-
1.发明公开公开(公告)号：US20230285603A1
公开(公告)日：2023-09-14
申请号：US17963823
申请日：2022-10-11
申请人： Cornell University
CPC分类号： A61K51/0482 , A61P35/00 , A61K51/0497 , A61K51/0402
摘要： The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.
-
公开(公告)号：US20220194904A1
公开(公告)日：2022-06-23
申请号：US17390284
申请日：2021-07-30
申请人： Cornell University
IPC分类号： C07D249/06 , C07C275/16 , A61B6/03 , A61K9/00 , A61K51/04 , C07C275/24
摘要： The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220177461A1
公开(公告)日：2022-06-09
申请号：US17678793
申请日：2022-02-23
申请人： Cornell University
IPC分类号： C07D413/14 , A61K51/04 , A61K51/10
摘要： The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
-
4.发明授权公开(公告)号：US11285227B2
公开(公告)日：2022-03-29
申请号：US16500380
申请日：2018-04-05
申请人： CORNELL UNIVERSITY
摘要： The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.
-
5.发明申请公开(公告)号：US20210128757A1
公开(公告)日：2021-05-06
申请号：US16500380
申请日：2018-04-05
申请人： CORNELL UNIVERSITY
摘要： The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20200317588A1
公开(公告)日：2020-10-08
申请号：US16772706
申请日：2018-12-20
申请人： Cornell University
发明人： John W. Babich
摘要： The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.
-
公开(公告)号：US12103922B2
公开(公告)日：2024-10-01
申请号：US17678803
申请日：2022-02-23
申请人： Cornell University
IPC分类号： C07D413/14 , A61K51/04 , A61K51/10 , A61K45/06 , C07B59/00
CPC分类号： C07D413/14 , A61K51/0463 , A61K51/0482 , A61K51/1072 , A61K45/06 , C07B59/002
摘要： The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:
or a pharmaceutical y acceptable salt thereof,
or a pharmaceutically acceptable salt thereof,
or a pharmaceutically acceptable salt thereof,
wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.-
8.发明公开公开(公告)号：US20240050599A1
公开(公告)日：2024-02-15
申请号：US18113206
申请日：2023-02-23
申请人： Cornell University
CPC分类号： A61K51/0482 , A61P35/00 , A61K51/0497 , A61K51/0402
摘要： The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.
-
公开(公告)号：US20220274974A1
公开(公告)日：2022-09-01
申请号：US17678803
申请日：2022-02-23
申请人： Cornell University
IPC分类号： C07D413/14 , A61K51/04 , A61K51/10
摘要： The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutical y acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
-
10.发明申请公开(公告)号：US20220185803A1
公开(公告)日：2022-06-16
申请号：US17678782
申请日：2022-02-23
申请人： Cornell University
IPC分类号： C07D413/14 , A61K51/04 , A61K51/10
摘要： The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.018 秒)
